By redefining CD4+CD8a+ T cell as key effectors in lung repair and demonstrating nanotechnology-enhanced cytokine delivery, we established a template for biomimetic therapeutics in ARDS management. This evidence concerns the gene CD4 and acute respiratory distress syndrome.